Inogen, Inc. (NASDAQ:INGN) – Equities researchers at KeyCorp lowered their FY2021 earnings per share (EPS) estimates for shares of Inogen in a research note issued on Monday, January 10th. KeyCorp analyst M. Mishan now anticipates that the medical technology company will post earnings per share of ($0.03) for the year, down from their previous forecast of ($0.02). KeyCorp also issued estimates for Inogen’s FY2022 earnings at ($0.79) EPS and FY2023 earnings at ($0.27) EPS.
A number of other equities analysts have also recently commented on INGN. Stifel Nicolaus decreased their target price on shares of Inogen from $70.00 to $40.00 and set a “hold” rating on the stock in a research report on Monday, November 8th. Needham & Company LLC upgraded shares of Inogen from a “hold” rating to a “buy” rating and set a $47.00 target price for the company in a research report on Thursday, December 9th. SVB Leerink dropped their price target on shares of Inogen from $72.00 to $42.00 and set a “market perform” rating for the company in a research report on Friday, November 5th. Finally, JPMorgan Chase & Co. upgraded shares of Inogen from an “underweight” rating to a “neutral” rating and dropped their target price for the stock from $71.00 to $45.00 in a research report on Tuesday, November 2nd. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Inogen currently has an average rating of “Hold” and a consensus price target of $51.33.
Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Thursday, November 4th. The medical technology company reported $0.53 EPS for the quarter, beating the consensus estimate of ($0.29) by $0.82. The business had revenue of $93.11 million during the quarter, compared to the consensus estimate of $86.69 million. Inogen had a net margin of 3.21% and a return on equity of 3.11%. The company’s revenue was up 25.3% on a year-over-year basis. During the same period in the previous year, the business earned ($0.08) earnings per share.
Several institutional investors and hedge funds have recently bought and sold shares of INGN. Millennium Management LLC grew its stake in Inogen by 471.9% in the third quarter. Millennium Management LLC now owns 278,886 shares of the medical technology company’s stock valued at $12,017,000 after purchasing an additional 230,124 shares in the last quarter. Ziegler Capital Management LLC acquired a new position in shares of Inogen in the 3rd quarter valued at $4,984,000. Caas Capital Management LP acquired a new stake in Inogen during the 2nd quarter worth $7,410,000. Vanguard Group Inc. raised its stake in shares of Inogen by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 2,351,418 shares of the medical technology company’s stock valued at $153,242,000 after purchasing an additional 101,579 shares during the period. Finally, Ghisallo Capital Management LLC acquired a new stake in shares of Inogen in the 3rd quarter valued at about $4,250,000. 93.10% of the stock is currently owned by institutional investors.
Inogen Company Profile
Inogen, Inc engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products consists of Inogen One G4 system, Inogen One G3 system, Inogen One G5 system, Inogen TAV, and Inogen at Home.
Further Reading: What is Cost of Capital?
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.